Latest Financial Results
Q2 2023

Latest Annual Filing
For Fiscal Year Ending September 30, 2022
Report Links
Email Alerts
Sign up today and receive company updates straight to your inbox.

Company Overview
NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase’s targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neuromuscular, neurological and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions.
IR Contacts
Headquarters
NeuBase Therapeutics, Inc.
350 Technology Drive
Pittsburgh, PA 15219
T: 412-763-3350
info@neubasetherapeutics.com
Transfer Agent
Standard Registrar and Transfer Company
440 East 400 South
Suite 200
Salt Lake City, UT 84111
T: 801-571-8844